Basic Information

Gene symbol S Synonyms E2 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description spike glycoprotein

GTO ID GTC2750
Trial ID NCT05000216
Disease Pemphigus Vulgaris | Juvenile Rheumatoid Arthritis | Systemic Lupus Erythematosus | Rheumatoid Arthritis | Multiple Sclerosis | Childhood Type Dermatomyositis | Systemic Sclerosis
Altered gene S
Therapeutic/Target gene Therapeutic gene
TherapymRNA vaccine
Treatment BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax;mRNA-1273,Bivalent|BNT162b2, Bivalent
Co-treatment MMF or MPA
Location approved UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US;NULL
PhasePhase2
Recruitment statusActive, Not Recruiting
TitleBooster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01)
Year2021
CountryUnited States
Company sponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Other ID(s)DAIT ACV01|NIAID CRMS ID#: 38873
Vector information
Vectoradenovirus|lipid nanoparticle

Clinical Result

Cohort1: Moderna mRNA-1273_Continue IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort2: BNT162b2_Continue IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort3: Ad26.COV2.S_Continue IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort4: Moderna mRNA-1273_Withhold IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort5: BNT162b2_Withhold IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort6: Ad26.COV2.S_Withhold IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort7: Moderna mRNA-1273_Continue IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort8: BNT162b2_Continue IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort9: Ad26.COV2.S_Continue IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort10: Moderna mRNA-1273_Withhold IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort11: BNT162b2_Withhold IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort12: Ad26.COV2.S_Withhold IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort13: Moderna mRNA-1273_Continue IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort14: BNT162b2_Continue IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort15: Ad26.COV2.S_Continue IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort16: Withhold IS (MMF or MPA)_BNT162b2_Moderna mRNA-1273, Bivalent_BNT162b2, Bivalent
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort17: Withhold IS (MTX)_Moderna mRNA-1273, Bivalent_BNT162b2, Bivalent
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort18: Ad26.COV2.S_Withhold IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort19: Withhold IS (B cell depletion therapy)_Moderna mRNA-1273, Bivalent_BNT162b2, Bivalent
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort20: Moderna mRNA-1273_Withhold IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort21: Monovalent [B.1.351] CoV2 preS dTM-AS03_Withhold IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort22: Monovalent [B.1.351] CoV2 preS dTM-AS03_Withhold IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort23: Monovalent [B.1.351] CoV2 preS dTM-AS03_Withhold IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort24: Moderna mRNA-1273, Bivalent_Continue IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort25: BNT162b2, Bivalent_Continue IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort26: Moderna mRNA-1273, Bivalent_Withhold IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort27: BNT162b2, Bivalent_Withhold IS (MMF or MPA)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort28: Moderna mRNA-1273, Bivalent_Continue IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort29: BNT162b2, Bivalent_Continue IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort30: Moderna mRNA-1273, Bivalent_Withhold IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort31: BNT162b2, Bivalent_Withhold IS (MTX)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort32: Moderna mRNA-1273, Bivalent_Continue IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort33: BNT162b2, Bivalent_Continue IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort34: BNT162b2, Bivalent_Withhold IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult
Cohort35: Moderna mRNA-1273, Bivalent_Withhold IS (B cell depletion therapy)
Administration route intramuscular injection
Age Child, Adult, Older_Adult

Relationship Graph

Overview of Knowledge Graph